IN8BIO, Inc.
INAB4.170USD
+4.049+3372.11%
Cierre 06/06, 16:00（ET）Cotizaciones retrasadas 15 min
338.85MCap. mercado
PérdidaP/E TTM
Más Datos de IN8bio Inc Compañía
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Información de la empresa
Código de la empresaINAB
Nombre de la empresaIN8bio Inc
Fecha de salida a bolsaNov 12, 2020
Fundada en2018
Director ejecutivoMr. William T. Ho
Número de empleados18
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 12
DirecciónEmpire State Building
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10118
Teléfono16466006438
Sitio Webhttps://www.in8bio.com
Código de la empresaINAB
Fecha de salida a bolsaNov 12, 2020
Fundada en2018
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William T. Ho
Mr. William T. Ho
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: vie., 16 de may
Hora de actualización: vie., 16 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Bios Equity Partners, LP.
8.32%
Franklin Advisers, Inc.
5.51%
Ho (William Tai Wei)
2.71%
Alyeska Investment Group, L.P.
2.01%
The Vanguard Group, Inc.
1.74%
Other
79.69%
Estadísticas de accionistas
Accionista
Proporción
Bios Equity Partners, LP.
8.32%
Franklin Advisers, Inc.
5.51%
Ho (William Tai Wei)
2.71%
Alyeska Investment Group, L.P.
2.01%
The Vanguard Group, Inc.
1.74%
Other
79.69%
Tipo
Accionista
Proporción
Venture Capital
8.39%
Investment Advisor/Hedge Fund
8.31%
Individual Investor
4.30%
Hedge Fund
2.09%
Investment Advisor
1.09%
Private Equity
1.09%
Research Firm
0.02%
Other
74.72%
Participación institucional
Hora de actualización: lun., 3 de mar
Hora de actualización: lun., 3 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
64
36.86M
46.48%
+9.17M
2024Q4
64
40.67M
56.11%
+11.42M
2024Q3
66
26.31M
53.00%
+3.73M
2024Q2
66
26.43M
54.24%
+1.59M
2024Q1
62
24.15M
55.92%
+314.96K
2023Q4
58
23.08M
53.43%
+4.41M
2023Q3
55
17.49M
62.06%
+5.54M
2023Q2
52
17.21M
67.21%
+7.01M
2023Q1
46
16.24M
65.08%
+6.18M
2022Q4
45
8.68M
40.92%
-6.62M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bios Equity Partners, LP.
8.60M
10.58%
--
--
Dec 31, 2024
Franklin Advisers, Inc.
5.70M
7.01%
+5.70M
--
Dec 31, 2024
Ho (William Tai Wei)
2.80M
3.45%
--
--
Feb 16, 2025
Alyeska Investment Group, L.P.
5.06M
6.23%
+4.63M
+1.06K%
Dec 31, 2024
The Vanguard Group, Inc.
1.42M
1.75%
--
--
Dec 31, 2024
AIGH Capital Management, LLC.
4.64M
5.71%
-2.10M
-31.09%
Dec 31, 2024
Brandt (Peter C)
622.89K
0.77%
--
--
Feb 16, 2025
Sigma Planning Corporation
1.04M
1.28%
+190.10K
+22.33%
Dec 31, 2024
Geode Capital Management, L.L.C.
515.19K
0.63%
+185.92K
+56.46%
Dec 31, 2024
Roemer (Alan S.)
299.87K
0.37%
--
--
Feb 16, 2025
Ver más
ETFs relacionados
Hora de actualización: vie., 6 de jun
Hora de actualización: vie., 6 de jun
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
